|Chemical and physical data|
|Molar mass||145.9 kg/mol|
Aducanumab is a human monoclonal antibody that is being studied for the treatment of Alzheimer's disease (AD). It is being developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer. The antibody targets aggregated forms of β-amyloid.
Interim results from the second Phase 1 study of the drug were reported at the 12th International Conference on Alzheimer’s and Parkinsons’s Diseases and Related Neurological Disorders (AD/PD 2015), in Nice, France, in March 2015. A phase Ib study was published in August 2016 and the phase 3 clinical trial is ongoing.
- Cynthia Fox for Drug Discovery and Development. April 28, 2015 The Story of Biogen's Alzheimer's Drug, Aducanumab
- Rebecca Zacks for Xconomy. November 20th, 2007 Biogen Inks $380 Million Deal With Swiss Company
- Toyn, Jeremy (2015). "What lessons can be learned from failed Alzheimer's disease trials?". Expert Rev. Clin. Pharmacol. 8 (3): 267–269. doi:10.1586/17512433.2015.1034690. PMID 25860157.
- Matthew Herper for Forbes. March 20, 2015 Biogen Drug Could Inspire New Hope For Alzheimer's Treatments
- Sevigny J.; Chiao P.; Bussière T.; Weinreb P.H.; Williams L.; Maier M.; Dunstan R.; Salloway S.; Chen T.; Ling Y.; O'Gorman J.; Qian F.; Arastu M.; Li M.; Chollate S.; Brennan M.S.; Quintero-Monzon O.; Scannevin R.H.; Arnold H.M.; Engber T.; Rhodes K.; Ferrero J.; Hang Y.; Mikulskis A.; Grimm J.; Hock C.; Nitsch R.M.; Sandrock A. (2016). "The antibody aducanumab reduces Aβ plaques in Alzheimer's disease". Nature. 537 (7618): 50–56. doi:10.1038/nature19323.